bluuebunny/crossref_metadata_2025_split huggingface dataset:
A Multicenter Study of Colorectal Adenomas Rationale, Objectives, Methods and Characteristics of the Study Cohort
Authors: Bruzzi Paolo ,   * The SMAC Workgroup is reported in the Appendix.
Published: April 2018

Background and Aims The Multicenter Study of Colorectal Adenomas (SMAC) is a retrospective-prospective cohort study involving four Gastrointestinal Endoscopy Units in Italy. The main aim of the study is to evaluate the relationship between clinical and pathologic information at index colonoscopy and subsequent incidence of adenoma and colorectal carcinoma. We report the rationale, objectives and methods of the study, including patient characteristics at initial presentation. Methods All patients were consecutively identified from the endoscopy registries of the four Centres from January 1, 1985 to December 31, 1992. Inclusion criteria were: age 18-69 years, endoscopy performed with adequate toilette at least up to the rectosigmoid junction, and removal of all detectable polyps. Exclusion criteria were: familial adenomatous polyposis, inflammatory bowel diseases, adenocarcinoma in adenoma with infiltrated margins, previous invasive cancer at any site, colon resection and geographic inaccessibility. Results Out of 20,071 patients who underwent endoscopy at the four Centres, 11,959 fulfilled the eligibility criteria (5,892 males and 6,067 females, mean age = 51.1 ± 11.6 years). The main reasons for exclusion were age (n = 4,020) and previous or present colorectal cancer (n = 2,389). Symptoms were the most common reason for referral (72.3%), while post-polypectomy follow-up and positive fecal occult blood accounted for most of the remaining cases. A pancolonoscopy was performed in 3,088 patients (25.8%), while a left-sided endoscopy was performed in 7,887 (66%). A total number of 4,810 polyps were removed from 2,699 patients (2,994 adenomas, 1,580 hyperplastic polyps and 236 polyps lost after resection). A significant association (p < 0.001) between age and the endoscopic findings was observed. The subjects without polyps (n = 9,198) had the lowest age (mean = 49.9; 95%CL = 49.6 - 50.1) followed by the patients with hyperplastic polyps (n = 661; mean age = 52.3; 95%CL = 51.5-53.1), and the patients with adenomas (n = 1,732; mean age = 56.2; 95%CL = 55.8 - 56.6), and the patients with hyperplastic polyps and adenomas (n = 306; mean age = 57.2; 95%CL = 56.3 - 58.2). Polyps were diagnosed more frequently in males than in females (28.6% versus 17.0%; p < 0.0001). Conclusion This study provides some insights in the natural history of colorectal cancer and stresses the need to develop adequate strategies in the follow-up of subjects after either positive or negative colonoscopy.
Hairy Cell Leukemia: An Ultrastructural Study of Hairy Cells before and after Interferon Therapy
Authors: Morroni Manrico , Cinti Saverio 
Published: April 2018

Aims and background To test the diagnostic relevance of the presence of ribosome-lamellae complexes (RLC) in 18 hairy cell leukemia (HCL) cases, and to correlate clinical response to interferon (IFN) therapy with hairy cell ultrastructural modifications in 5 of these cases. Methods Peripheral blood samples of 18 HCL patients were studied by transmission electron microscopy. Five of these patients received IFN treatment and subsequently were evaluated at different intervals for ultrastructural modifications of the peripheral blood. Results RLC were observed in 66.66% of our 18 HCL patients, but in less than 1% of all the cases contained in the files (consisting of over 8,000 cases) of our Electron Microscopy Unit. The microvilli disappeared after IFN therapy in the patients who did not display RLC before therapy (2 cases), whereas they were fewer, shortened and blunted, but still evident, in the cases where RLC had been observed before therapy (3 cases). Moreover, in the HCL cases with pre-therapy RLC, neoplastic cells still synthesized RLC after IFN treatment, but their morphologic aspect was immature. Conclusions Our study suggests that: 1) the presence of RLC, when associated to the hairy aspect of the cells, has considerable diagnostic value even though RLC are observed in other rare neoplastic and non-neoplastic conditions; 2) HCL cases with pre-therapy RLC exhibited a morphologic response to IFN therapy different from that of cases without pre-therapy RLC; 3) the quantitative and qualitative modifications of RLC following IFN treatment, as yet unexplained, are probably related to IFN action, in line with a previous report.
Clinical Efficacy of Cancer Subcutaneous Immunotherapy with Interleukin-2 in Relation to the Pretreatment Levels of Tumor Growth Factor Insulin-Like Growth Factor-1
Authors: Lissoni Paolo , Barni Sandro , Ardizzoia Antonio , Frigerio Franco , Paolorossi Franco , Cazzaniga Marina , Tancini Gabriele , Rocco Francesco , Aapro Matti 
Published: April 2018

Aims and background IGF-1 has been proven to be one of the most important growth factors for normal and neoplastic cells. Abnormally high levels of IGF-1 have been observed in cancer patients. Since it has been demonstrated that some growth factors may counteract the action of antitumor cytokines, the presence of increased IGF-1 concentrations could reduce the efficacy of cancer biotherapies with cytokines, such as IL-2. The present study was performed to evaluate the efficacy of IL-2 immunotherapy in relation to the pretreatment levels of IGF-1 in advanced cancer patients. Methods The study included 20 consecutive patients with metastatic renal cell cancer who were treated subcutaneously with IL-2 at 6 million IU/day for 5 days/week for 6 weeks. IGF-1 serum levels were measured by RIA on venous blood samples collected before the immunotherapy, after 3 weeks, and at the end of IL-2 injection. Results Objective tumor regressions were obtained in 5/20 patients, consisting of 1 complete response (CR) and 4 partial responses (PR). Nine patients had stable disease and the last 6 patients progressed. Abnormally high pretreatment levels of IGF-1 were seen in 13/20 patients. The percent of clinical responses (CR + PR) was significantly higher in patients with normal pretreatment concentrations of IGF-1 than in those with elevated levels (4/7 vs 1/13, P < 0.01). No significant changes in mean IGF-1 levels occurred during IL-2 therapy. However, mean IGF-1 levels increased in progressing patients and decreased in those with a response or stable disease, even though none of the differences was statistically significant. Conclusions The study showed that high pretreatment levels of IGF-1 are associated with a reduced efficacy of IL-2 immunotherapy of renal cancer. Further studies are required to establish whether IGF-1 levels simply reflect the extension of disease, or whether they may influence per se the action of IL-2.
A Case of Breast Angiosarcoma: Diagnostic Imaging and Review of the Literature
Authors: Zincone Gian Emilio , Perego Paolo , Rossi Gian Marco , Bovo Giorgio 
Published: April 2018

Primary angiosarcoma of the breast is a rare tumor, with approximately 170 cases reported in the literature (1-3, 10, 11, 15). Reports on the imaging characteristics of these tumors have been occasional until a recent review by Liberman et al. (11). Diagnostic imaging of the masses include mammographic and ultrasound examinations (5): the imaging characteristics of the tumor can be nonspecific and sometimes heterogeneous (11). Only recently was one case evaluated with magnetic resonance imaging (11). We present the mammographic and sonographic features of a case of primary angiosarcoma of the breast with an inflammatory appearance.
Bone Marrow Biopsy for the Staging of Non-Hodgkin's Lymphoma: Bilateral or Unilateral Trephine Biopsy?
Authors: Luoni Marco , Declich Paolo , De Paoli Alberto , Fava Sergio , Marinoni Patrizia , Montalbetti Luigi , Sangalli Gabriele , Sciuccati Patrizia , Tocci Antonio , Tosi Anna , Assi Agnese , Cassi Edmondo 
Published: April 2018

Aim The occurrence of unilateral involvement in bilateral bone marrow trephine biopsies in non-Hodgkin's lymphomas (NHL) at disease onset (10-20% of cases) has been reported since the early 70s. Therefore, although these studies were based on small series, the use of bilateral bone marrow biopsies has become the rule. However, the clinical value of this procedure has never been clearly established. The aim of the present study was to ascertain the true value of bilateral bone marrow biopsy in the staging of NHL. Study Design We examined 368 cases of NHL (A-H according to the Working Formulation) (WF), without leukemic involvement of the peripheral blood, in order to evaluate: 1) the incidence of unilateral bone marrow involvement; 2) the percentage of patients who, as a result of unilateral bone marrow involvement, changed from stages I-II to stage IV; 3) assessment of response to therapy for patients with both bilateral or unilateral bone marrow involvement. Results In the A-C NHL groups of WF there was a unilateral bone marrow involvement of 8.8%. Overall, bone marrow involvement induced a change from clinical stages I-II to stage IV in 5.6% of cases, a figure which would correspond to a false negative rate of 2.8%, if unilateral bone marrow biopsy was performed. In the D-F and G, H groups of WF, unilateral involvement was 10.1% and 8.5% respectively; the change in stage from I-II to IV by unilateral bone marrow involvement respectively amounted to 1.4% and 2.8%, which correspond to respective false negative rates of 0.7% and 1.4%. Conclusions On the basis of these results and of the present therapeutic strategies, we propose: bilateral bone marrow biopsy for clinical stages I-II of all NHL; no bone marrow biopsy at disease onset for clinical stages III and IV of A to H histologic subtypes of the WF; unilateral bone marrow biopsy (A-C subtypes of the WF) or bilateral (D-H of the WF), after the regression of extramedullary localizations.
Solitary Thyroid Metastasis from a Renal Cell Carcinoma Diagnosed and Treated 12 Years before: A Case Report
Authors: Innocente Roberto , Bortolus Roberto , De Paoli Antonino , Boz Giovanni , Gobitti Carlo , Cicuta Gianni , Sulfaro Sandro , Trovò Mauro G. 
Published: April 2018

The authors report a case of a solitary thyroid metastasis in a 62-year-old woman. The clinical history of the patient and the histologic findings are consistent with a renal origin of the tumor. Gli Autori riportano un caso di metastasi unica tiroidea in una donna di 62 anni. I dati anamnestici ed i reperti anatomo-patologici suggeriscono una origine renale della neoplasia.
Phase II Trial of Oral Tegafur and Folinic Acid with Mitoxantrone as First-Line Regimen in Patients with Metastatic Breast Cancer
Authors: Alonso Vicente , Santander Carmen , Florián Jesús , Alonso Martina , Isla Ma Dolores , Escudero Pilar , Sáenz Alberto , Tres Alejandro 
Published: April 2018

Background Tegafur acts as a deport form of 5-fluorouracil when administered orally for longs periods of time, since it is an active drug in metastatic breast cancer, with response rates of 29-44%. Biochemical modulation with folinic acid and the addition of mitoxantrone could increase the efficacy of tegafur in patients with metastatic breast cancer. Methods A prospective phase II trial in patients with previously untreated metastatic breast cancer was carried out. The scheme consisted of mitoxantrone, 12 mg/m2 intravenous day 1, oral tegafur, 750 mg/m2/day divided in three equal doses, and leucovorin 15 mg/8 h orally for days 1-21, given in a 4-week schedule. None patient had received chemotherapy for metastatic breast cancer, although 16 patients had received previous adjuvant chemotherapy. Results Thirty-four patients were included. Objective responses were achieved in 20 of 32 patients assessable for response, with 1 complete response and 19 partial responses. The objective response rate was 62.5% (95% confidence intervals, 48-76%). The median duration of response was 10 months. Grade III-IV toxicity according to WHO criteria was digestive (nausea/vomiting) in 12.5%, diarrhea in 25% and stomatitis in 25% of patients. Other toxicities were low. Eight patients required dose-reduction. Conclusions We achieved a significant response rate with the scheme, which was administered on an outpatient basis. It seems to be safe and effective as first-line treatment in metastatic breast cancer, with a short median response duration. The size of the trial does not permit definitive conclusions, and the role of biochemical modulation of tegafur in combination with mitoxantrone remains to be defined.
Oncostress: Evaluation of Burnout in Lombardy
Authors: Barni Sandro , Mondin Roberto , Nazzani Renato , Archili Caterina 
Published: April 2018

Aims This study was carried out to evaluate how working with oncologic patients (from various points of view) can cause personal discomfort for the operator. Methods Questionnaires (n=406) consisting of many requisites concerning personal and professional factors, organizational and work aspects were evaluated. They were given to oncologic doctors, radiotherapists, various specialists, nurses and radiotherapy technicians in Lombardy. Results The study revealed a state of anxiety in 52.7% of subjects and depression in 16%, mainly in the professional nursing categories and in particular in women and the young. The most singular aspects observed were not related to work organization. Conclusions Working in an oncologic environment is, in different ways, the cause of “oncostress” and distinctly induces burnout. However, it appears to be less significant in Italy than indicated in the literature.
Chromogranin-A Expression in Neoplastic Neuroendocrine Cells and Prognosis in Colorectal Cancer
Authors: Secco Giovanni Battista , Campora Elisabetta , Fardelli Roberto , Lapertosa Gabriella , De Lucchi Francesca , Gianquinto Daniela , Bonfante Pierfrancesco 
Published: April 2018

Aims Chromogranin-A (CG), a cytoplasmic glycoprotein, is one of the markers most frequently used to identify the presence of neuroendocrine cells in the human gastrointestinal tract. Several authors have identified a subgroup of colorectal cancer patients with a severe prognosis whose tumors contained neuroendocrine CG-positive cells. In the present study, CG expression in 100 patients with colorectal adenocarcinoma treated from January 1983 to December 1988 with potentially curative surgery was analyzed and correlated with other prognostic factors and 5-year survival rate. Methods Samples tested immunohistochemically for CG were divided into three groups: I) negative; II) less than 1 CG-positive cell/mm2; III) more than 1 CG-positive cell/mm2. Results Of 100 patients with primary colorectal adenocarcinoma, 79% had tumors comprised of CG-negative cells, 17% had rare CG-positive cells, and 4% of cases could be classified in group III. No significant relation between CG expression and location of primary tumor, bowel wall infiltration, stage of disease or tumor grade according to Broders and Jass was observed. The 5-year survival was 53% and 52% for CG-positive and CG-negative lesions, respectively. Survival of patients with Dukes-Kirklin stage C and D was comparable in patients with CG-positive (33.3%) and CG-negative (30%) tumors. Conclusions CG expression cannot, at present, be recommended as a marker to identify prognostic subgroups in colorectal cancer patients.
Chemoprevention of Breast Cancer with Fenretinide (4-HPR): Study of Long-Term Visual and Ophthalmologic Tolerability
Authors: Mariani Luigi , Formelli Franca , De Palo Giuseppe , Manzari Antonia , Camerini Tiziana , Campa Tiziana , Di Mauro Maria Gaetana , Crippa Arnaldo , Grottaglie Maurizio Delle , Del Vecchio Marcella , Marubini Ettore , Costa Alberto , Veronesi Umberto 
Published: April 2018

Background Fenretinide (4-HPR) is a synthetic retinoid being clinically tested in the chemoprevention of different tumors and precancerous lesions. Though safer than many other retinoids in experimental models, in humans 4-HPR may induce adverse effects that mainly affect the eye and visual function. Such effects are thought to be caused by the reduction of plasma retinol levels, which occurs after administration of the retinoid. Methods A series of 826 women treated with 4-HPR was studied to quantify the incidence and temporal pattern of occurrence of visual (dark adaptation) and ophthalmologic complaints (ocular dryness, lacrimation, conjunctivitis or photophobia) and to investigate the possible association between their occurrence and plasma retinol levels. Results The cumulative incidence of visual complaints reached nearly 20% at 5 years. The occurrence of these symptoms was more frequent at the start of treatment. The probability of developing visual complaints was significantly higher in patients with lower plasma retinol concentrations following 4-HPR treatment. The cumulative incidence of ophthalmologic complaints was 8% at 5 years. The occurrence of these complaints was evenly distributed during treatment. Ophthalmologic complaints were not associated with a greater degree of reduction of plasma retinol concentrations, but rather with the patient's age, since symptomatic patients were generally older than asymptomatic patients. Conclusions Visual and ophthalmologic complaints are common during 4-HPR treatment: their estimated 5-year cumulative incidence is close to 20% and 8%, respectively. However, the pattern of occurrence over time and the underlying mechanisms of these two types of complaints seem different.
Complementary Medicine and Oncologists’ Attitudes: A Survey in Italy
Authors: Crocetti Emanuele , Crotti Nadia , Montella Maurizio , Musso Marco 
Published: April 2018

Aims and Background There is growing interest in medical practices other than conventional medicine (complementary medicine, CM). CM is widely used by cancer patients. The purpose of the present study was to evaluate the knowledge of and the attitude towards CM in a sample of Italian allopathic oncologists. Methods Seventy-six oncologists of the Istituto Nazionale per la Ricerca sul Cancro of Genoa, 80 oncologists working at the Istituto Tumori Fondazione Pascale of Naples, and 100 hospital practitioners of the Province of Sondrio were asked to answer a self-administered structured questionnaire on CM. The level of their knowledge on CM, their opinion on CM and on CM therapists, the sources of information, the use of CM for themselves, the practice of CM and the attitude to refer patients to CM were investigated. Results Replies were received from 190 oncologists. The response rate was significantly lower for the oncologists of Naples. One-fifth of the physicians replied that they had no knowledge of CM. The main sources of information were newspapers and TV. One-fourth of the physicians had personally used CM. About one-fourth of the physicians had practiced a kind of CM. The percentage of oncologists from Genoa who would refer their cancer patients to CM was significantly higher than the others. The physicians thought that about 84% of their patients used CM. The variables considered were tested in a multivariate model. The oncologists from Genoa showed a significantly increased risk of referring their patients to CM. Oncologists who had personally used CM referred patients to CM 3 times more frequently than the others. Conclusions A large percentage of cancer patients used CM according to their physicians. The level and the quality of the knowledge of CM of the oncologists interviewed were low. The oncologists could hardly be helpful for their patients in dealing with therapies different from conventional medicine.
Hydroxyurea Did Not Enhance the Clinical Response to Vinblastine in Patients with Anthracycline-Resistant Metastatic Breast Cancer
Authors: Huan Susan D. , Yau Jonathan C. , Tomiak Eva , Goel Rakesh , Cripps Christine , Gertler Stan Z. , Prosser Isobel A. , Stewart David J. 
Published: April 2018

Background Vinblastine is commonly used in metastatic breast cancer after anthracycline failure. The response rate to vinblastine is approximately 20%, with short duration of response. In vitro studies have shown that the addition of hydroxyurea resulted in increased accumulation of vinblastine in tumor cells and in loss of double minutes. We evaluated the combination of vinblastine and hydroxyurea in patients with anthracycline-resistant metastatic breast cancer. Patients and Methods Fourteen assessable patients with metastatic breast cancer were entered in the study. All patients had progressed on anthracyclines or progressed within 8 months of stopping anthracyclines. Patients received hydroxyurea (500 mg orally) every Monday, Wednesday and Friday starting one week before the first course of chemotherapy and continuing throughout treatment until disease progression. Vinblastine (6 mg/m2) was given intravenously every 21 days. Results The median number of courses for vinblastine was 3.5 (range, 1-6). Three patients had partial responses in soft tissue metastases (21%). Four patients had stable disease. Four patients had > grade 2 neutropenia, and 1 patient had grade 4 thrombocytopenia. There were 2 cases of grade 3 constipation, 2 of grade 3 nausea, and 1 each of grade 2 neuropathy and myalgia. There was no treatment-related mortality. Conclusions Low-dose hydroxyurea in combination with vinblastine has a 21% response rate in metastatic breast cancer after anthracycline failure. Toxicity was mild and generally reversible. At the adopted dose schedule of hydroxyurea, the antitumor activity of vinblastine in anthracycline-resistant metastatic breast cancer did not appear to be enhanced.
Intramedullary Teratoma: Case Report and Review of the Literature
Authors: Caruso Riccardo , Antonelli Mariano , Cervoni Luigi , Salvati Maurizio 
Published: April 2018

Aims and Background Intramedullary teratoma is an extremely exceptional tumor (5 cases), although a careful review of international literature has shown it to be more frequent (32 cases) than believed. Methods The authors present a personal case with some unusual aspects. Results Our case is unusual not only because it was diagnosed by MRI (only one case has been reported in the literature) but also because surgical removal of the tumor was apparently total (only 4 other cases have been described), with a long follow-up period (4.5 years) and excellent results, in clinical and neuroradiologic terms.
Postoperative Radiotherapy and Surgery in Stage I Endometrial Carcinoma: A 10-Year Experience
Authors: Boz Giovanni , De Paoli Antonino , Innocente Roberto , Talamini Renato , Scarabelli Carlo , Scozzari Giovanni , Trovò Mauro G. 
Published: April 2018

Background Data from the literature show that the incidence of pelvic recurrences in poor prognosis endometrial carcinoma is significantly reduced by combined surgery and radiotherapy compared to surgery alone. Methods In this paper we analyze the results of the combined treatment surgery plus adjuvant irradiation in patients with endometrial carcinoma with regard to survival, site of progression, and toxicity. The surgical treatment consisted of total abdominal hysterectomy and bilateral salpingo-oophorectomy. Pelvic and para-aortic node dissection was performed. Results The overall 5-year survival was 88%. Three patients had local failure. Ten patients with local control of disease had distant metastases and 2 had local and distant recurrences. Conclusions Our experience confirms the data of the literature. Postoperative irradiation is a safe and well tolerated treatment which can achieve good local control in high-risk stage I endometrial carcinoma. The control of distant metastases remains an open issue.